Understanding of hepatitis drug market at home and abroad

Viral hepatitis is a group of infectious diseases including hepatitis A, B, C, D and E, affecting millions of people around the world About 1.5 million people die of hepatitis every year, mainly hepatitis B and C So what is the global and national use of this segment? From 2010 to 2013, among the top 500 best-selling drugs in the world, the market of anti hepatitis virus drugs (excluding interferon and vaccine) is generally stable, and the market of hepatitis B is always ahead of that of hepatitis C However, with the advent of the Gilead super heavy bomb sovaldi at the end of 2013, the market for hepatitis C has grown rapidly and continues to trigger a research boom in this field Among the top 500 best-selling drugs in 2014, the anti hepatitis virus drugs used to treat hepatitis B include entecavir, lamivudine and adefovir, and another five hepatitis C drugs are among the top 500 As a whole, entecavir, as a safe and effective drug recommended by who in the latest version of hepatitis B infection treatment guidelines, has been in the hepatitis B market for a long time; while sofibuproir, a variety, accounts for nearly 60% of the whole hepatitis market share, while making outstanding contributions to the global top 500 market According to PDB data of China Pharmaceutical Industry Information Center in the domestic market, from 2010 to 2014, the amount of anti hepatitis virus drugs (excluding interferon and vaccine) increased year by year, with a compound growth rate of 29.59% Affected by the slowing down of the overall growth rate of sample hospitals, the growth rate of this segment fell significantly in 2013, but it was always higher than the average growth rate of the sample hospital market Over the years, the market structure of antiviral drugs has been relatively stable If not included in the small amount of traditional Chinese medicine yanyanyanling injection, entecavir, A Duff Vee and telbivudine are respectively in the top three in this segment In terms of growth in the past five years, entecavir is far ahead of other varieties, with a compound annual growth rate of 41.70% in five years Adefovir's drug purchase amount decreased in 2014 and may be surpassed by telbivudine in the future In 2014, the largest amount of drug purchased by entecavir was boluting produced by Shanghai Squibb Pharmaceutical Co., Ltd of China and the United States, followed by entecavir dispersible tablets produced by Shandong Lukang Pharmaceutical Co., Ltd., which accounted for more than 90% of the whole entecavir market Gilead's sovaldi has been suffering from price disputes since it was launched Even if the product is expected to be the best-selling product in the world (the global sales in 2014 is only second to the autoinflammatory drug sumerial), it still can't break through the door of the Chinese market The health and Family Planning Commission once said that the price of sovaldi is "unattainable" and the purchase way is "far away".